TY  - JOUR 
AU  - Batalla Cebey, Ana
AU  - Suh Oh, Hae Jin
AU  - Carretero Hernández, G.
AU  - Miquel-Miquel, J.
AU  - Botella-Estrada, R.
AU  - Martorell-Calatayud, A.
AU  - Sanz-Motilva, V.
AU  - Figueras-Nart, I.
AU  - Florez Menendez, Maria Angeles
PY  - 2023
SN  - 2768-6566
UR  - http://hdl.handle.net/20.500.11940/21798
AB  - Background: The oral anti-janus kinase 1 inhibitor upadacitinib has shown a good efficacy-safety profile in the treatment of moderate-to-severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been...
LA  - eng
TI  - Observational 24-week study to assess clinical response to upadacitinib posttrial in patients with moderate-to-severe atopic dermatitis
DO  - 10.1002/jvc2.179
T2  - JEADV Clinical Practice
M2  - 571
KW  - AS Pontevedra
KW  - CHUP
KW  - AS Pontevedra
KW  - CHUP
KW  - AS Santiago
KW  - CHUS
VL  - 2
ER  -